Contact information
Research groups
DPhil Supervisor Profile
David Kerr
CBE FMedSci FRCP
Professor of Cancer Medicine
- Consultant Physician
In collaboration with Dr Rachel Midgley, Oncology Clinical Trials Office, we have conducted a series of international adjuvant trials of chemotherapy for colorectal cancer. In parallel, we have established a biorepository of tissue and constitutional DNA (n=3500) which has allowed us to collaborate with Ian Tomlinson to generate a number of cancer susceptibility SNPs and commercial partners to characterise a prognostic mRNA signature which assists in selection of patients for chemotherapy. We are currently developing biomarkers for the anti-angiogenic agent bevacizumab.
Key publications
-
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.
Journal article
Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557
Recent publications
-
The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care.
Journal article
Kerr D. et al, (2019), Oncologist
-
Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage
Journal article
GLAIRE M. et al, (2019), British Journal of Cancer
-
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Journal article
Law PJ. et al, (2019), Nat Commun, 10
-
Confirmation that somatic mutations of beta-2 microglobulin correlate with a lack of recurrence in a subset of stage II mismatch repair deficient colorectal cancers from the QUASAR trial.
Journal article
Barrow P. et al, (2019), Histopathology
-
Oxford Textbook of Cancer Biology
Book
Pezzella F. et al, (2019)